Triomics has secured $22 million in Series B funding, marking a significant expansion phase for its AI platform designed to combat information overload in oncology. This capital infusion, led by new investor Andreessen Horowitz and existing backer General Catalyst, will fuel the scaling of their technology and further enhance patient care. The company plans to leverage these funds to expand its team and accelerate product development.
Amount: $22.0M
